ஜூலியன் திரடோ ரிவேச் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

By Jim Shelton
February 24, 2021
Share this with FacebookShare this with TwitterShare this with LinkedInShare this with EmailPrint this
Yale scientists have developed a new class of antiviral agents that shows promise for creating COVID-19 therapeutics exhibiting particular effectiveness when used in tandem with the drug remdesivir, another antiviral medication approved for use against the virus.
The new compounds are the first potent, drug-like, non-covalent, and non-peptidic inhibitors of the main protease, or enzyme, in SARS-CoV-2 that is crucial for processing essential viral proteins. A study demonstrating the compounds appears in the journal ACS Central Science.
The work is the latest collaboration of Yale researchers William Jorgensen and Karen Anderson, senior co-authors of the study, who use high-level computation and structural biology methods to design compounds that target viral proteins. ....

Farren Isaacs , William Jorgensen , Elizabeth Stone , Mohammad Ghahremanpour , Brett Lindenbach , Scott Miller , Yuka Takeo , Krasimir Spasov , Julian Tirado Rives , Joseph Ippolito , Shuo Zhang , Karen Anderson , Chun Hui Zhang , Shalley Kudalkar , Zhuobin Liang , Maya Deshmukh , Yale University School Of Medicine , Us National Institutes Of Health , Yale Cancer Center , Sterling Professor , Yale Cancer , Additional Yale , Yale University School , Yale University , Press Releases , ஃப்யாரந் ஐஸக்ஸ் ,